2022
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 497-530. PMID: 35545176, DOI: 10.6004/jnccn.2022.0025.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNCCN Clinical Practice GuidelinesCell lung cancerClinical practice guidelinesLung cancerPractice guidelinesMetastatic non-small cell lung cancerMetastatic lung cancerNCCN guidelinesPrimary treatmentTargeted therapyActionable mutationsPatientsCancerSubsequent treatmentTherapyOncologyTreatmentGuidelinesImmunotherapyRelapseDiagnosis
2020
First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial
Hochmair M, Camidge, Kim H, Ahn M, Yang J, Han J, Lee K, Delmonte A, Campelo G, Kim D, Griesinger F, Felip E, Califano R, Spira A, Gettinger S, Tiseo M, Ni Q, Zhang P, Popat S. First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial. Pneumologie 2020, 74: 131-131. DOI: 10.1055/s-0039-3403360.Peer-Reviewed Original Research
2019
Immune Checkpoint Inhibitor–Associated Pericarditis
Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL. Immune Checkpoint Inhibitor–Associated Pericarditis. Journal Of Thoracic Oncology 2019, 14: 1102-1108. PMID: 30851443, PMCID: PMC6617516, DOI: 10.1016/j.jtho.2019.02.026.Peer-Reviewed Original ResearchConceptsAdverse eventsCTLA-4 inhibitorsImmune checkpoint inhibitorsDeath-1/Pericardial window procedureCheckpoint inhibitorsThird patientClinical presentationCardiac toxicityHistopathologic findingsSide effectsPericarditisPatientsDeath ligandsPotential mechanismsWindow procedureInhibitorsImmunotherapyNSCLCCardiotoxicityAutopsiesTherapy
2018
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original ResearchPityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin
Coleman E, Panse G, Haldas J, Gettinger SN, Leventhal JS. Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAAD Case Reports 2018, 4: 669-671. PMID: 30112450, PMCID: PMC6091308, DOI: 10.1016/j.jdcr.2018.06.022.Peer-Reviewed Original ResearchFirst comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
Papadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Langer C, Edelman M, Aggarwal C, Socinski M, Gettinger S, Waqar S, Griffin K, Leighl N, Owonikoko T, Bradley J, Ramalingam S, Stinchcombe T, Blanke C, Kelly K, Herbst R. First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. Journal Of Clinical Oncology 2018, 36: 9019-9019. DOI: 10.1200/jco.2018.36.15_suppl.9019.Peer-Reviewed Original ResearchClinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.Peer-Reviewed Original ResearchConceptsPD-1 axis inhibitorsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerInhibitor therapyLocal therapyLymph nodesLung cancerSurvival rateSolid Tumors v1.1Response Evaluation CriteriaSite of diseaseProgression of diseaseProgressive diseaseClinical patternLN metastasisSuch patientsClinical featuresMedian timeRadiographic featuresTumor regressionProlonged benefitPatientsTherapyResponse criteria
2017
Immuno-thermal ablations – boosting the anticancer immune response
Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations – boosting the anticancer immune response. Journal For ImmunoTherapy Of Cancer 2017, 5: 78. PMID: 29037259, PMCID: PMC5644150, DOI: 10.1186/s40425-017-0284-8.Peer-Reviewed Original ResearchConceptsImmune responseImmune effectsRobust antitumor responseAnticancer immune responseImmune modulating drugsUse of immunomodulationSystemic antitumor activityCheckpoint blockadeAntitumor responseAblative therapyCombination therapyRadiofrequency ablationAblative techniquesModulating drugsAnimal modelsAntitumor activityThermal ablationTherapeutic appealImmunomodulationTherapyAblationResponseMonotherapyImmunomodulatorsCryoablationScientific Advances in Thoracic Oncology 2016
Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. Journal Of Thoracic Oncology 2017, 12: 1183-1209. PMID: 28579481, DOI: 10.1016/j.jtho.2017.05.019.Peer-Reviewed Original ResearchConceptsLung cancer careLung cancer researchValue of careAdjuvant therapyThoracic cancerCancer careLung cancerThoracic oncologyCare provideEarly detectionKinase inhibitorsGenomic testingImmunotherapyTherapyCancerCancer researchCareMultiple areasMolecular diagnosticsAnnual updateConcise reviewNSCLCInternational AssociationSurgeryMesothelioma84O Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial
Peters S, Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. 84O Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Annals Of Oncology 2017, 28: ii29-ii30. DOI: 10.1093/annonc/mdx091.004.Peer-Reviewed Original ResearchAtezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study
Eberhardt W, Garassino M, Rizvi N, Besse B, Jänne P, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017, 71: s1-s125. DOI: 10.1055/s-0037-1598277.Peer-Reviewed Original ResearchOA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study
Garassino M, Rizvi N, Besse B, Jänne P, Christoph D, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. Journal Of Thoracic Oncology 2017, 12: s251-s252. DOI: 10.1016/j.jtho.2016.11.239.Peer-Reviewed Original Research
2016
Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis
Magnuson W, Amini A, Patil T, Kavanagh B, Camidge D, Braunstein S, Boreta L, Attia A, Rana N, Contessa J, Gettinger S, Lester-Coll N, Yu J, Chiang V. Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s57-s58. DOI: 10.1016/j.ijrobp.2016.06.149.Peer-Reviewed Original ResearchAssociation of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal Of Kidney Diseases 2016, 68: 287-291. PMID: 27113507, DOI: 10.1053/j.ajkd.2016.02.057.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisPD-1 inhibitor therapyInhibitor therapyInterstitial nephritisLung cancerNon-small cell lung cancerAnti-PD-1 antibodyAcute kidney injuryImmune checkpoint inhibitorsT cell immunityCell lung cancerLung cancer patientsClinical trial dataRenal toleranceCheckpoint inhibitorsKidney injuryDeath-1Kidney biopsyCancer patientsPatientsTrial dataTherapyAdverse effectsDrugsNephritis
2014
Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer
Politi K, Gettinger S. Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer. Clinical Cancer Research 2014, 20: 5576-5578. PMID: 25228532, PMCID: PMC4401422, DOI: 10.1158/1078-0432.ccr-14-2306.Commentaries, Editorials and Letters
2013
Late recurrence of basaloid carcinoma initially treated as a small cell lung cancer
Shumaster V, Bae JW, Gettinger SN, Cai G, Kim AW. Late recurrence of basaloid carcinoma initially treated as a small cell lung cancer. Journal Of Thoracic Disease 2013, 5: e68-70. PMID: 23585963, PMCID: PMC3621916, DOI: 10.3978/j.issn.2072-1439.2013.03.01.Peer-Reviewed Case Reports and Technical Notes
2011
A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer
Gettinger S, Lynch T. A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics In Chest Medicine 2011, 32: 839-851. PMID: 22054890, DOI: 10.1016/j.ccm.2011.08.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerLung cancerEpidermal growth factor receptor (EGFR) mutational statusProspective randomized clinical trialsRandomized clinical trialsClinical characteristicsClinical trialsTraditional chemotherapyMutational statusTherapyHistologyCancerHomogeneous populationTreatmentChemotherapyPatientsDecades of advancesTrialsBiomarkers
2010
Targeted therapy for thyroid cancer: An updated review of investigational agents.
Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid cancer: An updated review of investigational agents. Current Opinion In Investigational Drugs 2010, 11: 661-8. PMID: 20496261.Peer-Reviewed Original ResearchConceptsMedullary thyroid cancerThyroid cancerEarly phase clinical trialsPapillary thyroid cancerRandomized trialsInvestigational agentsClinical trialsTargeted therapyPotential therapyPromising drugXL-184CancerTreatmentUpdated reviewTherapyTrialsMolecular mechanismsSunitinibMalignancySorafenibVandetanibBRAFVEGFRCarcinogenesis